Premier Fund Managers Ltd Takes Position in Repligen Co. (NASDAQ:RGEN)

Premier Fund Managers Ltd bought a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,113 shares of the biotechnology company's stock, valued at approximately $592,000.

Several other institutional investors and hedge funds have also bought and sold shares of RGEN. UMB Bank n.a. grew its position in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 110 shares during the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Repligen during the 4th quarter valued at $216,000. Worldquant Millennium Advisors LLC grew its holdings in shares of Repligen by 11.9% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 50,276 shares of the biotechnology company's stock valued at $7,482,000 after purchasing an additional 5,337 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Repligen by 1.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 363,379 shares of the biotechnology company's stock worth $54,078,000 after purchasing an additional 5,478 shares during the period. Finally, Van ECK Associates Corp boosted its position in Repligen by 7.8% during the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock valued at $6,078,000 after buying an additional 3,066 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Up 2.2 %

Repligen stock traded up $2.77 during mid-day trading on Wednesday, reaching $131.27. The stock had a trading volume of 159,865 shares, compared to its average volume of 674,973. Repligen Co. has a one year low of $113.50 and a one year high of $182.52. The company has a 50-day moving average price of $152.75 and a two-hundred day moving average price of $148.00. The company has a market capitalization of $7.37 billion, a price-to-earnings ratio of -257.40, a PEG ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on RGEN. HC Wainwright reissued a "buy" rating and issued a $180.00 price target on shares of Repligen in a report on Friday, February 21st. TD Cowen initiated coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 target price on the stock. Royal Bank of Canada upped their price target on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research report on Friday, February 21st. Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective on the stock. Finally, JPMorgan Chase & Co. upped their target price on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $178.64.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax acquired 250 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.